UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models

1, 2014

Volltextzugriff (PDF)

Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes

PloS one, 2014-01, Vol.9 (1), p.e86919

2014

Volltextzugriff (PDF)

Dose–response and Cardiopulmonary Side Effects of the Novel Neuromuscular-blocking Drug CW002 in Man

Anesthesiology (Philadelphia), 2016-12, Vol.125 (6), p.1136-1143

2016

Volltextzugriff (PDF)

Retrospective Analysis Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation Offers Improvements in Efficiency of the Design of Volunteer Infection Studies for Antimalarial Drug Development

Clinical and translational science, 2021-03, Vol.14 (2), p.712-719

2021

Volltextzugriff (PDF)

A Physiologically Based Pharmacokinetic Modeling Approach to Assess the Potential for Drug Interactions Between Trofinetide and CYP3A4-Metabolized Drugs

Clinical therapeutics, 2024-03, Vol.46 (3), p.194-200

2024

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Relationships Describing the Efficacy of Oritavancin in Patients with Staphylococcus aureus Bacteremia

Antimicrobial Agents and Chemotherapy, 2006-03, Vol.50 (3), p.994-1000

2006

Volltextzugriff (PDF)

Population pharmacokinetic meta-analysis of trabectedin (ET-743, yondelis®) in cancer patients

Clinical pharmacokinetics, 2007-01, Vol.46 (10), p.867-884

2007

Volltextzugriff (PDF)

Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment

Cancer chemotherapy and pharmacology, 2008-06, Vol.62 (1), p.135-147

2008

Volltextzugriff (PDF)

Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients

Antimicrobial agents and chemotherapy, 2017-08, Vol.61 (8), p.e00207

2017

Volltextzugriff (PDF)

Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung Cancer

European journal of drug metabolism and pharmacokinetics, 2023-11, Vol.48 (6), p.675-689

2023

Volltextzugriff (PDF)

Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma

Cancer chemotherapy and pharmacology, 2010-11, Vol.66 (6), p.1039-1049

2010

Volltextzugriff (PDF)

Pharmacokinetic/Pharmacodynamic Model of CW002, an Investigational Intermediate Neuromuscular Blocking Agent, in Healthy Volunteers

Anesthesiology (Philadelphia), 2018-06, Vol.128 (6), p.1107-1116

2018

Volltextzugriff (PDF)

Use of Pharmacodynamic End Points in the Evaluation of Gatifloxacin for the Treatment of Acute Maxillary Sinusitis

Clinical infectious diseases, 2004-06, Vol.38 (11), p.1513-1520

2004

Volltextzugriff (PDF)

Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients

Journal of clinical pharmacology, 2016-12, Vol.56 (12), p.1538-1549

2016

Volltextzugriff (PDF)

CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population

Pharmacogenomics, 2016-04, Vol.17 (6), p.603-613

2016

Volltextzugriff (PDF)

Development and Validation of a UPLC Method for Rapid and Simultaneous Analysis of Proton Pump Inhibitors

AAPS PharmSciTech, 2015-02, Vol.16 (1), p.30-34

2015

Volltextzugriff (PDF)

Pharmacokinetic Studies in Healthy Subjects for the Development of an Extended-Release Tablet Formulation of Guaifenesin: A 505(b)(2) New Drug Application Approval

Clinical pharmacology in drug development, 2013-01, Vol.2 (1), p.25-32

2013

Volltextzugriff (PDF)

Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects

Diagnostic microbiology and infectious disease, 2004-10, Vol.50 (2), p.95-102

2004

Volltextzugriff (PDF)

Characterizing plasma albumin concentration changes in TB/HIV patients on anti retroviral and anti –tuberculosis therapy

In silico pharmacology, 2014-09, Vol.2 (1), p.3-3, Article 3

2014

Volltextzugriff (PDF)

Challenges in the transition to model-based development

The AAPS journal, 2005-10, Vol.7 (2), p.E488-E495

2005

Volltextzugriff (PDF)

Introduction to Model Evaluation

Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models, 2014, p.212-231

2014

Volltextzugriff (PDF)

PK/PD Models

Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models, 2014, p.250-264

2014

Volltextzugriff (PDF)

Applications Using Parameter Estimates from the Individual

Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models, 2014, p.198-211

2014

Volltextzugriff (PDF)

Population Model Concepts and Terminology

Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models, 2014, p.9-27

2014

Volltextzugriff (PDF)

Quality Control

Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models, 2014, p.285-292

2014

Volltextzugriff (PDF)

1 – 25 von 477

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(376)
Mit Volltextzugriff
(392)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(476)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(256)
Life Sciences & Biomedicine
(192)
Humans
(136)
Female
(78)
Male
(77)
Physical Sciences
(54)
Social Sciences
(48)
Middle Aged
(40)
Adult
(39)
Animals
(37)
Biological And Medical Sciences
(36)
Pharmacology & Pharmacy
(36)
Aged
(33)
Medical Sciences
(32)
Science & Technology - Other Topics
(29)
Multidisciplinary Sciences
(24)
Technology
(24)
Business & Economics
(23)
Chemistry
(23)
Neurosciences & Neurology
(23)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models

Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes

Dose–response and Cardiopulmonary Side Effects of the Novel Neuromuscular-blocking Drug CW002 in Man

Retrospective Analysis Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation Offers Improvements in Efficiency of the Design of Volunteer Infection Studies for Antimalarial Drug Development

A Physiologically Based Pharmacokinetic Modeling Approach to Assess the Potential for Drug Interactions Between Trofinetide and CYP3A4-Metabolized Drugs

Pharmacokinetic-Pharmacodynamic Relationships Describing the Efficacy of Oritavancin in Patients with Staphylococcus aureus Bacteremia

Population pharmacokinetic meta-analysis of trabectedin (ET-743, yondelis®) in cancer patients

Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment

Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients

Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung Cancer

Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma

Pharmacokinetic/Pharmacodynamic Model of CW002, an Investigational Intermediate Neuromuscular Blocking Agent, in Healthy Volunteers

Use of Pharmacodynamic End Points in the Evaluation of Gatifloxacin for the Treatment of Acute Maxillary Sinusitis

Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients

CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population

Development and Validation of a UPLC Method for Rapid and Simultaneous Analysis of Proton Pump Inhibitors

Pharmacokinetic Studies in Healthy Subjects for the Development of an Extended-Release Tablet Formulation of Guaifenesin: A 505(b)(2) New Drug Application Approval

Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects

Characterizing plasma albumin concentration changes in TB/HIV patients on anti retroviral and anti –tuberculosis therapy

Challenges in the transition to model-based development

Introduction to Model Evaluation

PK/PD Models

Applications Using Parameter Estimates from the Individual

Population Model Concepts and Terminology

Quality Control

Suchergebnisse filtern